Park Ha Biological Technology (BYAH) Common Equity (2023 - 2025)

Park Ha Biological Technology's Common Equity history runs 3 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Common Equity rose 165.25% year-over-year to $4.0 million; the TTM figure through Oct 2025 stood at $4.0 million (up 165.25% YoY), while the FY2025 annual figure was $4.0 million, up 165.25% from the prior year.
• Common Equity was $4.0 million for Q4 2025 at Park Ha Biological Technology, up from $1.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $4.0 million in Q4 2025 to a low of $1.0 million in Q4 2023.
• Historically, Common Equity has averaged $2.2 million across 3 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 48.75% in 2024, then soared 165.25% in 2025.
• A 3-year view of Common Equity shows it stood at $1.0 million in 2023, then soared by 48.75% to $1.5 million in 2024, then jumped by 165.25% to $4.0 million in 2025.
• The last three Common Equity figures came in at $4.0 million (Q4 2025), $1.5 million (Q4 2024), and $1.0 million (Q4 2023), per Business Quant data.